DCM
CLDX icon

Driehaus Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Driehaus Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-292,292
Closed -$9.96M – 373
2022
Q1 		$9.96M Sell
292,292
-223,197
-43% -$7.13M 0.12% 233
2021
Q4 		$19.9M Sell
515,489
-35,576
-6% -$1.55M 0.2% 150
2021
Q3 		$29.8M Sell
551,065
-34,246
-6% -$1.61M 0.35% 85
2021
Q2 		$19.6M Buy
585,311
+236,471
+68% +$6.49M 0.26% 132
2021
Q1 		$7.19M Sell
348,840
-44,375
-11% -$1.02M 0.11% 247
2020
Q4 		$6.89M Sell
393,215
-8,548
-2% -$154K 0.11% 215
2020
Q3 		$5.96M Buy
401,763
+281,763
+235% +$3.3M 0.12% 189
2020
Q2 		$1.56M Buy
+120,000
New +$532K 0.04% 269
2015
Q3 		– Sell
-852
Closed -$322K – 550
2015
Q2 		$322K Sell
852
-643
-43% -$255K 0.01% 485
2015
Q1 		$625K Buy
+1,495
New +$535K 0.02% 445
2014
Q1 		– Sell
-21,275
Closed -$7.73M – 515
2013
Q4 		$7.73M Sell
21,275
-298
-1% -$115K 0.28% 107
2013
Q3 		$11.5M Buy
+21,573
New +$7.4M 0.44% 58

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Driehaus Capital Management's CLDX Position: Q2 2022 in Review

Driehaus Capital Management sold out of Celldex Therapeutics (CLDX) in Q2 2022, closing a stake of 292,292 shares — an estimated $9.96M sold.

Driehaus Capital Management first reported a position in CLDX in Q3 2013 and held it in 12 quarters. The position peaked at $29.8M in Q3 2021. 157 funds tracked by Wall St. Rank hold CLDX as of Q2 2022.

  • Driehaus Capital Management reported no remaining Celldex Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Driehaus Capital Management sold 292,292 Celldex Therapeutics shares in Q2 2022, an estimated $9.96M.
  • Driehaus Capital Management first reported a position in Celldex Therapeutics in Q3 2013 and held it in 12 quarters.
  • Driehaus Capital Management's Celldex Therapeutics position peaked at $29.8M in Q3 2021.
  • 157 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2022.

Based on Driehaus Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.